<DOC>
	<DOC>NCT00975806</DOC>
	<brief_summary>The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.</brief_summary>
	<brief_title>Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>1. Metastatic Renal Cell Carcinoma. 2. Eastern Cooperative Oncology Group (ECOG) performance status of â‰¤ 1. 1. Prior chemotherapy. 2. Prior treatment with lenalidomide, thalidomide, pomalidomide, or sunitinib. 3. Laboratory values outside normal ranges. 4. Myocardial infarction (MI) within past 12 months. 5. Current congestive heart failure.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>